| Market cap | $68.67M |
|---|---|
| Enterprise value | N/A |
| Revenue | $4.699M |
|---|---|
| EBITDA | N/A |
| Income | -$79.58 |
| Revenue Q/Q | 21.36% |
| Revenue Y/Y | -7.28% |
| P/E | 0.00 |
|---|---|
| Forward P/E | N/A |
| EV/Sales | 148.14 |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| PEG | N/A |
| Price/Sales | 14.61 |
| P/FCF | N/A |
| Price/Book | -2.14 |
| Book/Share | -1.33 |
| Cash/Share | 0.80 |
| FCF yield | -68.16% |
| Volume | 7.605k / 45.000 |
|---|---|
| Relative vol. | 169.00 × |
| EPS | N/A |
|---|---|
| EPS Q/Q | 9.09% |
| Est. EPS Q/Q | 21.74% |
| Profit margin | -1,524.51% |
|---|---|
| Oper. margin | -846.39% |
| Gross margin | 100.00% |
| EBIT margin | -1,598.85% |
| EBITDA margin | -5,560.50% |
| Ret. on assets | -73.56% |
|---|---|
| Ret. on equity | 389.04% |
| ROIC | -68.40% |
| ROCE | -728.64% |
| Debt/Equity | -4.07 |
|---|---|
| Net debt/EBITDA | 2.17 |
| Current ratio | 0.38 |
| Quick ratio | 0.38 |
| Volatility | 7.47% |
|---|---|
| Beta | 0.89 |
| RSI | 54.20 |
|---|
| Insider ownership | 73.07% |
|---|---|
| Inst. ownership | 3.89% |
| Shares outst. | 36.155M |
|---|---|
| Shares float | 0.000 0.00% |
| Short % of float | 0.38% |
| Short ratio | 3.83 |
| Dividend | N/A |
|---|---|
| Dividend yield | N/A |
| Payout ratio | N/A |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | 14 Aug 2024 |
Wednesday, 9 March 2022
|
|
| Armata Pharmaceuticals to move headquarters to Playa Vista | |
Wednesday, 5 January 2022
|
|
| Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs | |
Thursday, 18 November 2021
|
|
| Armata Pharmaceuticals Provides Regulatory and Clinical Update Reflecting Sustained Progress Across Key Phage Therapeutic Development Programs | |
Wednesday, 10 November 2021
|
|
| Armata Pharmaceuticals Announces Third Quarter Results and Provides General Corporate Update | |
Tuesday, 2 November 2021
|
|
| Armata Enters Lease to Build State-of-the-Art R&D and GMP Manufacturing Facility | |
Thursday, 13 May 2021
|
|
| SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Armata Pharmaceuticals Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors - Yahoo Finance | |
Thursday, 18 March 2021
|
|
| Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Results and Provides General Corporate Update | |
Wednesday, 17 March 2021
|
|
| Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $20 Million Private Placement with Innoviva | |
Tuesday, 16 March 2021
|
|
| Armata Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference | |
Wednesday, 27 January 2021
|
|
| Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Development Programs | |
Friday, 11 September 2020
|
|
| Armata Pharmaceuticals Announces Participation in Upcoming Investor Conferences | |
Thursday, 19 March 2020
|
|
| Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Results and Provides General Corporate Update | |
Thursday, 13 February 2020
|
|
| Armata Pharmaceuticals Announces Closing of First Tranche of Recently Executed $25 Million Securities Purchase Agreement with Innoviva, Inc. | |
Tuesday, 4 February 2020
|
|
| 85 Biggest Movers From Yesterday | |
Monday, 3 February 2020
|
|
| 61 Stocks Moving In Monday's Mid-Day Session | |
Wednesday, 29 January 2020
|
|
| Company News For Jan 29, 2020 | |
| 70 Biggest Movers From Yesterday | |
Tuesday, 28 January 2020
|
|
| 46 Stocks Moving In Tuesday's Mid-Day Session | |
| Insider |
Trans.
Transaction
|
Total value |
|---|---|---|
| Inc.Innoviva Strategic Oppo... | Buy 31 Mar 2022 | $26,926,040 |
| Inc.Innoviva Strategic Oppo... | Buy 9 Feb 2022 | $18,073,960 |
| Inc.Innoviva Strategic Oppo... | Buy 29 Oct 2021 | $4,000,003 |
| Inc.Innoviva Strategic Oppo... | Buy 17 Mar 2021 | $13,929,289 |
| Inc.Innoviva Strategic Oppo... | Buy 26 Jan 2021 | $6,070,714 |
| Inc. Innoviva, 10% owner | Buy 27 Mar 2020 | $22,149,687 |
Powered by
Robintrack.
| Insider | Age | Since | Compensation |
|---|---|---|---|
| Todd R. Patrick MBA (58) Advisor and Director | 58 | $773,250 | |
| Dr. Brian Varnum Ph.D. (61) CEO and Director | 61 | $558,250 | |
| Steven R. Martin (60) Chief Financial Officer | 60 | $490,000 | |
| Robin Kramer | 2020 | ||
| Mina Pastagia | 2020 | ||
| Sarah Schlesinger (60) Director since 2020 | 60 | 2020 | |
| Odysseas Kostas (45) Director since 2020 | 45 | 2020 | |
| Todd Peterson | 2019 | ||
| Heather Jones | 2019 | ||
| Joseph Patti | 2019 | ||
| Richard Bastiani | 2019 | ||
| Duane Morris | 2019 | ||
| Igor Bilinsky (47) Chief Operating Officer and Senior Vice President since 2017 | 47 | 2017 | |
| Steven Martin (54) Chief Financial Officer since 2016 | 54 | 2016 | |
| Todd Patrick | 2019 | ||
| Brian Varnum | 2019 | ||
| Erin Butler | |||
| Dr. Mina Pastagia M.D., MS | |||
| Duane Alfred Morris BA (71) VP of Operations | 71 | ||
| Dr. Wenyuan Shi Ph.D. |
c3 jian is a well-capitalized, private, los angeles based biotechnology company advancing novel compounds that target unmet medical/dental needs related primarily to oral healthcare. the company's lead compound is a unique peptide drug against dental caries (i.e. tooth decay). the company’s lead compound started fda-regulated phase ii human clinical trials in early 2014. c3 jian's platform technology has also yielded peptides that can affect calcification processes, including not only tooth sensitivity but possibly hair and nail growth as well. the company has recently moved its operations to a new facility in marina del rey. the company was founded based on technology created in the laboratory of dr. wenyuan shi, chair of the department of oral biology at the university of california, los angeles school of dentistry. for more information about the company and to explore career opportunities at c3 jian please visit our webpage at www.c3-jian.com
- Energy > Oil & Gas Exploration & Production
- Armata Pharmaceuticals Inc, 4503 Glencoe Avenue, Marina del Rey 90292, United States
- 858 829 0829
- Investor relations
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $43.34 | $19.243 | |||
| Short term investments | |||||
| Net receivables | $1.714 | $3.363 | |||
| Inventory | |||||
| Total current assets | $41.717 | $19.151 | |||
| Long term investments | |||||
| Property, plant & equipment | $56.943 | $57.276 | |||
| Goodwill & intangible assets | $3.49 | $3.49 | |||
| Total noncurrent assets | $78.639 | $79.212 | |||
| Total investments | |||||
| Total assets | $120.356 | $98.363 | |||
| Current liabilities | |||||
| Accounts payable | $4.61 | $5.689 | |||
| Deferred revenue | |||||
| Short long term debt | $104.165 | $9.481 | |||
| Total current liabilities | $110.045 | $16.461 | |||
| Long term debt | $63.744 | $110.89 | |||
| Total noncurrent liabilities | $66.821 | $113.967 | |||
| Total debt | $167.909 | $120.371 | |||
| Total liabilities | $176.866 | $130.428 | |||
| Stockholders' equity | |||||
| Retained earnings | -$333.84 | -$308.819 | |||
| Other stockholder equity | |||||
| Total stockholder equity | -$56.51 | -$32.065 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $19.243 | $20.812 | ||
| Short term investments | ||||
| Net receivables | $3.363 | |||
| Inventory | ||||
| Total current assets | $19.151 | $27.047 | ||
| Long term investments | ||||
| Property, plant & equipment | $57.276 | $46.652 | ||
| Goodwill & intangible assets | $3.49 | $3.49 | ||
| Total noncurrent assets | $79.212 | $68.787 | ||
| Total investments | ||||
| Total assets | $98.363 | $95.834 | ||
| Current liabilities | ||||
| Accounts payable | $5.689 | $6.034 | ||
| Deferred revenue | ||||
| Short long term debt | $9.481 | $17.011 | ||
| Total current liabilities | $16.461 | $24.873 | ||
| Long term debt | $110.89 | $31.804 | ||
| Total noncurrent liabilities | $113.967 | $34.881 | ||
| Total debt | $120.371 | $48.815 | ||
| Total liabilities | $130.428 | $59.754 | ||
| Stockholders' equity | ||||
| Retained earnings | -$308.819 | -$239.774 | ||
| Other stockholder equity | ||||
| Total stockholder equity | -$32.065 | $36.08 | ||
Income statement
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | $0.966 | $1.528 | |||
| Cost of revenue | |||||
| Gross profit | $0.966 | $1.528 | |||
| Operating activities | |||||
| Research & development | $8.016 | $7.928 | |||
| Selling, general & administrative | $3.178 | $3.179 | |||
| Total operating expenses | $11.194 | $11.107 | |||
| Operating income | -$10.228 | -$9.579 | |||
| Income from continuing operations | |||||
| EBIT | -$23.201 | -$18.397 | |||
| Income tax expense | |||||
| Interest expense | $1.82 | $1.45 | |||
| Net income | |||||
| Net income | -$25.021 | -$19.847 | |||
| Income (for common shares) | -$25.021 | -$19.847 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4.529 | $5.508 | ||
| Cost of revenue | ||||
| Gross profit | $4.529 | $5.508 | ||
| Operating activities | ||||
| Research & development | $33.77 | $35.017 | ||
| Selling, general & administrative | $11.649 | $7.437 | ||
| Total operating expenses | $45.419 | $42.454 | ||
| Operating income | -$40.89 | -$36.946 | ||
| Income from continuing operations | ||||
| EBIT | -$66.419 | -$36.917 | ||
| Income tax expense | ||||
| Interest expense | $2.626 | |||
| Net income | ||||
| Net income | -$69.045 | -$36.917 | ||
| Income (for common shares) | -$69.045 | -$36.917 | ||
Cash flows
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Net income | -$25.021 | -$19.847 | |||
| Operating activities | |||||
| Depreciation | $0.317 | $0.293 | |||
| Business acquisitions & disposals | |||||
| Stock-based compensation | $0.534 | $0.193 | |||
| Total cash flows from operations | -$10.584 | -$8.106 | |||
| Investing activities | |||||
| Capital expenditures | -$0.25 | -$2.39 | |||
| Investments | |||||
| Total cash flows from investing | -$0.25 | -$2.39 | |||
| Financing activities | |||||
| Dividends paid | |||||
| Sale and purchase of stock | $0.042 | ||||
| Net borrowings | $34.889 | ||||
| Total cash flows from financing | $34.931 | -$0.043 | |||
| Effect of exchange rate | |||||
| Change in cash and equivalents | $24.097 | -$10.539 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Net income | -$69.045 | -$36.917 | ||
| Operating activities | ||||
| Depreciation | $0.972 | $0.892 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.938 | $3.105 | ||
| Total cash flows from operations | -$47.423 | -$32.481 | ||
| Investing activities | ||||
| Capital expenditures | -$8.134 | -$2.211 | ||
| Investments | ||||
| Total cash flows from investing | -$8.134 | -$2.211 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.005 | $44.516 | ||
| Net borrowings | $54.026 | |||
| Total cash flows from financing | $53.988 | $44.016 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$1.569 | $9.324 | ||
Recent institutional transactions
| Quarter | Shareholder | Change |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|---|
| 2024 Q1 | Bridgeway Capital Management |
-43.01%
|
110,382 | $461,397 |
| 2024 Q1 | Seacrest Wealth Management |
+80.79%
|
32,777 | $137,008 |
| 2024 Q1 | Captrust Financial Advisors |
Opened
|
13,140 | $54,925 |
| 2024 Q1 | Bank Of America Corp de/ |
+0.34%
|
636,638 | $2,661,147 |
| 2024 Q1 | Tower Research Capital (trc) |
-49.60%
|
1,697 | $7,093 |
| 2024 Q1 | Qube Research & Technologies Ltd |
-4.88%
|
22,414 | $93,691 |
| 2024 Q1 | Blackrock |
+4.87%
|
23,868 | $99,768 |
| 2024 Q1 | Ubs Ag |
+76,600.00%
|
767 | $3,206 |
| 2024 Q1 | Morgan Stanley |
+21,200.00%
|
426 | $1,780 |
| 2024 Q1 | Royal Bank Of Canada |
-90.78%
|
26 | $0 |
Institutional shareholders
| Shareholder | Stake |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|
| Bank Of America Corp de/ | 1.76% | 636,638 | |
| Bridgeway Capital Management | 0.31% | 110,382 | |
| Geode Capital Management | 0.28% | 101,013 | |
| Edgewood Management | 0.28% | 100,000 | |
| Vanguard Group Inc | 0.25% | 90,969 | |
| Renaissance Technologies | 0.15% | 53,596 | |
| State Street Corp | 0.11% | 40,300 | |
| Seacrest Wealth Management | 0.09% | 32,777 | |
| Blackrock | 0.07% | 23,868 | |
| Qube Research & Technologies Ltd | 0.06% | 22,414 |
Sign up